

Study of vitamin D therapy to improve heart function and immune response in patients with chronic kidney disease (CKD)

Submission date 05/12/2010	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 05/04/2011	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 13/12/2019	Condition category Circulatory System	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr David Goldsmith

Contact details
Consultant Nephrologist and Reader in Renal Medicine
Guy's and St. Thomas' Hospital NHS Trust
Renal Offices
5th Floor Borough Wing
Great Maze Pond
London
United Kingdom
SE1 9RT

Additional identifiers

Protocol serial number
10/H0709/56

Study information

Scientific Title

Impact of vitamin D supplementation on left ventricular mass on cardiac magnetic resonance imaging and immune regulation in chronic kidney disease: a randomised placebo-controlled trial

Acronym

The 5C study

Study objectives

Native vitamin D repletion results in immune modulation and regression of left ventricular hypertrophy in vitamin D deficient non-dialysis dependent chronic kidney disease (CKD) patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

North London Research Ethics Committee (REC) 3, 02/06/2010, ref: 10/H0709/56

Primary study design

Interventional

Study design

Randomised double-blind placebo-controlled multicentre trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Left ventricular hypertrophy (LVH) in patients with non-dialysis dependent chronic kidney disease (CKD stage 3b and 4)

Interventions

Oral cholecalciferol therapy 100,000 IU at week 0, 4, 8, 12, 24 and 42 or matching placebo.

Intervention Type

Supplement

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Vitamin D

Primary outcome(s)

1. 10g improvement in left ventricular mass (LVM) with oral vitamin D therapy over 1 year
2. Difference in LVM in patients treated with vitamin D compared to controls

Measured at 52 weeks from enrolment.

Key secondary outcome(s)

1. Reduction in cardiac fibrosis determined by biomarkers of cardiac fibrosis in serum post vitamin D3 therapy

2. Augmentation of adaptive immune response to Hepatitis B vaccination post oral vitamin D3 supplementation
3. Immune regulation with predominantly antiinflammatory response with oral vitamin D3 therapy
4. Measured at 52 weeks from enrolment.

Completion date

10/03/2013

Eligibility

Key inclusion criteria

1. Patients aged 18 - 75 years with CKD stage 3b-4
2. Documented 25 hydroxy vitamin D deficiency/insufficiency with serum 25 (OH)D levels between 12.5 to 75 nmol/L
3. Left ventricular mass index (LVMI) between 80 - 160 g/m² for females and 100 - 160 g/m² for males
4. Patients on angiotensin converting enzyme inhibitors and/or angiotensin II receptor blockers

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Total final enrolment

48

Key exclusion criteria

1. Presence of diabetes mellitus (type I and II)
2. Serum calcium greater than 2.55 mmol/L
3. Anaemia (Hb less than 10.0 g/dL or taking regular erythropoiesis stimulating agents)
4. Known malignancy
5. History of congestive cardiac failure or ejection fraction less than 40% on ECHO and/or plasma NT-proBNP greater than 500 pg/ml
6. Uncontrolled hypertension (blood pressure [BP] greater than 150/90 mmHg despite anti-hypertensive medication)
7. Significant valvular heart disease identified on transthoracic ECHO
8. Conditions that may influence collagen metabolism such as recent (less than 6 months) surgery or trauma, fibrotic diseases or active inflammatory conditions
9. Immunosuppressive medications

- 10. Presence of arterio-venous fistula for dialysis access
- 11. History of previous myocardial infarction (Trop T greater than 0.5)

Date of first enrolment

10/01/2011

Date of final enrolment

10/03/2013

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Guy's and St. Thomas' Hospital NHS Trust

London

United Kingdom

SE1 9RT

Sponsor information

Organisation

Guy's and St. Thomas' NHS Foundation Trust (UK)

ROR

<https://ror.org/00j161312>

Funder(s)

Funder type

Charity

Funder Name

Guy's and St Thomas' Charity (UK)

Alternative Name(s)

Guy's and St Thomas' Charity, Guy's and St Thomas' Foundation, GSTTFoundation

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Funder Name

British Heart Foundation (BHF) (UK)

Alternative Name(s)

The British Heart Foundation, the_bhf, BHF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	12/12/2019	13/12/2019	Yes	No